Work

Depemokimab PK/PD in the 52-week randomised double-blind multicentre Phase III SWIFT-1 trial

Year: 2024

Type: conference-abstract

DOI: 10.1183/13993003.congress-2024.oa3647

Authors: Ian Pavord, Stein Schalkwijk, Anders Thorsted, Nicholas Bird, Loretta Jacques, Stepanie Korn

Institutions: University of Oxford, GlaxoSmithKline (United Kingdom), GlaxoSmithKline (Sweden)

Language: English

Topic: Asthma and respiratory diseases

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4404104274

Cites:

Cited by:

Related to: 10